5 results match your criteria: "Bristol Oncology and Haematology Centre[Affiliation]"

Article Synopsis
  • Capivasertib is a drug being tested as an addition to chemotherapy (docetaxel) for treating metastatic castration-resistant prostate cancer (mCRPC) based on encouraging preclinical results.
  • In a phase II trial, patients were randomly assigned to receive either capivasertib or a placebo alongside docetaxel, with the goal of assessing whether capivasertib could prolong progression-free survival (cPFS) and overall survival (OS).
  • Results showed that while median OS was significantly better with capivasertib (31.15 months) compared to placebo (20.27 months), there was no significant improvement in cPFS, suggesting further investigation is needed to confirm the findings.
View Article and Find Full Text PDF

Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available.

View Article and Find Full Text PDF

Statistical and Clinical Significance in the TERRA Study.

J Clin Oncol

May 2018

Paola Di Nardo, Bristol Oncology and Haematology Centre, Bristol, United Kingdom; and Alfredo Addeo, University Hospital Geneva, Geneva, Switzerland.

View Article and Find Full Text PDF

Background: Opioid use in patients with renal impairment can lead to increased adverse effects. Opioids differ in their effect in renal impairment in both efficacy and tolerability. This systematic literature review forms the basis of guidelines for opioid use in renal impairment and cancer pain as part of the European Palliative Care Research Collaborative's opioid guidelines project.

View Article and Find Full Text PDF

Aims: The most effective sequence of tamoxifen and both steroidal (SAIs) and non-steroidal aromatase inhibitors (NSAIs) has been extensively studied in the adjuvant setting. However, treatments for women who have failed initial aromatase inhibitor therapy in the metastatic setting have received relatively little attention. A systematic review was undertaken to assess the use of SAIs and NSAIs in metastatic breast cancer.

View Article and Find Full Text PDF